Kornimate/medical-research-clean huggingface dataset:
quantification of thrombocytes number and function in patients undergoing prolonged extracorporeal circulation

Conditions: Coagulopathy

Summary: prolonged extracorporeal circulation (ecc) for cardiac surgery results in coagulation abnormalities, most of which related to the direct, time dependent effect of the polymer tubing and the pump rollers on the thrombocytes. significant evidence demonstrates the effect of the duration of cardiopulmonary bypass on thrombocytes number and function, as well as on postoperative coagulopathy

quantification of the effect of ecc duration on blood coagulation and platelet number and function * observational study on 20 patients undergoing prolonged ecc * blood sampling every 30 minutes for platelet count, platelet adhesion markers and coagulation studies * blood test to be performed in rambam blood bank laboratory

Eligibility criteria:
inclusion criteria: * adults over 18 yo * scheduled for prolonged cardiac surgery requiring ecc time over 3 hours exclusion criteria: * documented coagulopathy * antiplatelet therapy other then aspirin
ropivacaine transversus abdominis plane blocks for cesarean section analgesia

Conditions: Postoperative Pain

Summary: with this research the investigators hope to determine the lowest dose of ropivacaine used in transversus abdominis plane (tap) blocks that can effectively treat pain in women after cesarean section (c-section).

with this research the investigators hope to determine the lowest dose of ropivacaine used in transversus abdominis plane (tap) blocks that can effectively treat pain in women after cesarean section (c-section). the tap is a space between the muscle layers of the abdominal wall that houses nerves supplying the abdominal skin. the investigators will inject the local anesthetic ropivacaine into this space to freeze these nerves and prevent pain following c-section. the investigators will compare three different doses of ropivacaine (0.5%, 0.25%, 0%) to determine the lowest dose that controls pain with the fewest side effects. participants in this study will receive 0.5% (group 1), 0.25% (group 2), or 0% (group 3) ropivacaine tap blocks to control pain after c-section. at 2, 6, 12, 24, and 48 hours after cesarean section visual analog pain scores (vas) for pain on movement, pain at rest, and pain with cough will be collected along with the time to first postoperative analgesic request, patient satisfaction scores, and patient demographics. the analgesic regimen will be considered effective if it provides lower average visual analog scores for pain with movement. secondary outcomes will be higher patient satisfaction, better pain control, fewer postoperative analgesic requests, and fewer side effects.

Eligibility criteria:
inclusion criteria: * pregnant patients undergoing elective c-section exclusion criteria: * allergy to local anesthetics * contraindication to tap blocks

Keywords: ropivacaine c-section analgesia tap block
pemetrexed in patients with advanced neuroendocrine tumors

Conditions: Neuroendocrine Tumors

Summary: the purpose of this study is to find out what effects (good and bad) pemetrexed has on patients with advanced neuroendocrine tumors.

* 1 cycle is equal to 21 days. every 21 days the following will be performed: a review of the patients symptoms and medications; physical exam; blood tests; vital signs; and pemetrexed infusion. * every 3 cycles (9 weeks) an assessment of disease extent by ct scan and a 24 hour urine collection (if applicable) will be performed. * before patients start receiving pemetrexed, they will be given folic acid, vitamin b12 and dexamethasone to help reduce the chance of significant side effects. dexamethasone will be taken the evening before, the morning before and the evening after receiving pemetrexed. folic acid should be taken daily beginning 5-7 days before the first dose of pemetrexed and should be continued for three weeks after the last dose of pemetrexed. vitamin b12 will be given as an injection 1-2 weeks before the first dose of pemetrexed and once every 9 weeks until 3 weeks after the last dose of pemetrexed. * patients can continue to receive treatment with pemetrexed unless there is evidence that their tumor has grown or they are experiencing serious side effects. * immediately after the patient has completed the study, they will be given a physical exam, including vital signs, a ct scan, and blood tets. the study staff will continue to monitor the patients health either by clinic visits or phone calls every three months for the remainder of your life.

Eligibility criteria:
inclusion criteria: * metastatic or locally unresectable neuroendocrine tumor, excluding small cell carcinoma * measurable tumor * 18 year of age or older * ecog performance status of 0,1 or 2 * life expectancy of greater than 12 weeks * wbc: \> 3.0/mm3 * plts: \> 100,000/mm3 * bilirubin: \< 2.0 mg/dl * ast \< 3 x uln (except in patients with known hepatic metastases wherein sst may be \< 5 x uln) * neutrophils \> 1000/mm3 * creatinine clearance \> 45 ml/min. should be measured using the standard cockroft-gault formula exclusion criteria: * prior treatment with pemetrexed * clinically apparent central nervous system metastases or carcinomatous meningitis * myocardial infarction in the past 6 months * major surgery in the past two weeks * uncontrolled serious medical or psychiatric illness * pregnant or lactating women

Keywords: pemetrexed neuroendocrine tumors metastatic neuroendocrine tumors
a study with lu ag09222 in adults with migraine who have not been helped by prior preventive treatments

Conditions: Migraine

Summary: researchers are trying to learn whether a drug called lu ag09222 can help prevent migraine headaches for people who have not been helped by other treatments that are used to prevent migraines. people who join this trial have tried 2 to 4 other medications to prevent their migraines, but these medications have not helped them. when the trial is over, researchers will use this information to find out if the number of migraine days decreased more for the participants who got either dose of lu ag09222 than for the participants who got the placebo.

participants will be randomly allocated to one of 3 treatment groups: lu ag09222 high dose, lu ag09222 low dose, or placebo, in a ratio of 2:1:2.

Eligibility criteria:
key inclusion criteria: * the participant has a diagnosis of migraine as defined by international classification of headache disorders third edition (ichd-3) guidelines confirmed at the screening visit. * the participant has a history of migraine onset at least 12 months prior to the screening visit. * the participant has a migraine onset at ≤50 years of age. * the participant has documented evidence of treatment failure in the past 10 years of at least 2 to 4 (maximum) different migraine preventive medications. key exclusion criteria: * the participant has been previously dosed with an anti-pituitary adenylate cyclase-activating polypeptide (anti-pacap) ligand-targeting antibody. * the participant has confounding and clinically significant pain syndromes. * the participant has a diagnosis of acute or active temporomandibular disorder. * the participant has a history or diagnosis of confounding headaches.
a dose-ranging safety and efficacy study of ecallantide to reduce surgical blood loss volume

Conditions: Bloodloss; Surgical Procedures, Operative

Summary: the purpose of this study is to assess the efficacy and identify the optimal dose(s) of ecallantide in reducing blood loss in subjects undergoing coronary artery bypass surgery including the use of cardio pulmonary bypass.


Eligibility criteria:
inclusion criteria: * written informed consent (by study subject or appropriate legal representative) prior to any study-related procedure not part of normal medical care * planned primary cabg surgery including the use of cardio-pulmonary bypass. exclusion criteria: * planned concomitant surgery including asd repair, valve replacement, carotid endarterectomy, cabg combined procedures or any repeat sternotomy; * body weight \<55 kg; * planned hypothermia (\<28ºc); * planned transfusion in the peri-operative or post-operative periods; * planned transfusion of pre-operatively donated autologous blood; * female subjects who are pregnant or lactating; * planned use of desmopressin, lysine analogs, atrial natriuretic hormone or recombinant activated factor vii; * planned use of corticosteroids in the pump prime solution; * ejection fraction \<30% within 90 days prior to surgery; * evidence of a myocardial infarction within 5 days prior to surgery; * history of stroke or transient ischemic attack within 3 months prior to surgery; * hypotension or heart failure requiring the use of inotropes or mechanical devices within 24 hours prior to surgery; * serum creatinine \>2.0 mg/dl within 48 hours prior to surgery; * serum hepatic enzymes above 2.5 times the upper limit of normal for the applicable laboratory; * hematocrit \<32% within 48 hours prior to surgery; * platelet count below the normal range for the applicable laboratory within 14 days prior to surgery; * history of, or family history of, bleeding or clotting disorder or thrombophilia; * history of heparin-induced thrombocytopenia; * prothrombin time and/or activated partial thromboplastin time \>1.5 x normal range; * serious intercurrent illness or active infection; * any previous exposure to ecallantide; * receipt of an investigational drug or device 30 days prior to participation in the current study; * known allergy to any agent expected to be used in the intra-operative or post-operative periods; and * administration of: eptifibatide within 6 hours prior to surgery, tirofiban hcl within 6 hours prior to surgery, \*enoxaparin sodium or other low-molecular-weight heparin \<24 hours prior to surgery, clopidogrel within 5 days prior to surgery, ticlopidine within 7 days prior to surgery, abciximab within 5 days prior to surgery, \*bivalirudin, argatroban or lepirudin within 6 hours prior to surgery, \*fondaparinux within 72 hours prior to surgery, prasugrel within 10 days prior to surgery \[\*prophylactic use permitted for the prevention of deep vein thrombosis.\]
observational registry on acute coronary syndromes in campania

Conditions: Acute Coronary Syndrome

Summary: this registry aims to collect data related to management of patients affected by acute coronary syndromes and hospitalized in the campania region of italy


Eligibility criteria:
inclusion criteria: * patients hospitalized for acute coronary syndromes exclusion criteria: * refuse to provide informed consent for study enrollment
monthly dosing of atacicept in igan

Conditions: IgA Nephropathy (IgAN); Berger Disease

Summary: this is a phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept

this phase 2 study is to explore the effectiveness, safety and tolerability of different dosing regimens of atacicept. regimens include monthly and weekly dosing.

Eligibility criteria:
inclusion criteria: * must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study assessments * adult male or female of ≥18 years of age, or as per country specific legally or nationally recognized adult age, who provides written informed consent prior to performing any study assessments * diagnosis of igan as demonstrated by renal biopsy conducted within 10 years * total urine protein excretion ≥0.75 g per 24-hour or urine protein-to-creatinine ratio (upcr) ≥0.75 mg/mg based on a 24-hour urine sample * egfr ≥30 ml/min/1.73 m2 at screening, as per the chronic kidney disease epidemiology collaboration (ckd-epi) * on a stable prescribed regimen of rasi (angiotensin converting enzyme inhibitor or angiotensin ii receptor blocker) for at least 8 weeks that is at the maximum labeled or tolerated dose at screening and from screening to study day 1 exclusion criteria: * igan secondary to another condition (eg, liver cirrhosis), or other causes of mesangial iga deposition including iga vasculitis (ie, henoch-schonlein purpura), systemic lupus erythematosus, dermatitis herpetiformis, ankylosing spondylitis * evidence of rapidly progressive glomerulonephritis (loss of ≥50% of egfr within 3 months of screening) * evidence of nephrotic syndrome within 6 months of screening (serum albumin \ 3.5 mg/mg) * renal or other organ transplantation prior to or expected during the study, with the exception of corneal transplants * concomitant chronic renal disease in addition to igan (eg, diabetic nephropathy, primary focal segmental glomerulosclerosis, membranous nephropathy, c3 glomerulopathy, lupus nephritis)
yttrium-90 radioembolization with glass microspheres (therasphere) for patients with hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: this is a prospective pilot study that will document the clinical experience of 30 patients with unresectable hepatocellular carcinoma undergoing liver-directed therapy with yttrium-90 glass microspheres (therasphere®).


Eligibility criteria:
inclusion criteria: * diagnosis of hepatocellular carcinoma with liver-dominant disease. diagnosis may be made by histo- or cyto-pathology, or by clinical and imaging criteria. * the cancer is unresectable. * all patients must be off all chemotherapeutic regimens for 30 days prior to and 30 days after therasphere treatment. * eastern cooperative oncology group (ecog) performance status of 0-2. * age 18 years or older. * able to understand informed consent. exclusion criteria: * evidence of potential delivery of greater than 16.5 mci (30 gy absorbed dose) of radiation to the lungs on either: * single therasphere administration; or * cumulative delivery of radiation to the lungs greater than 50 gy over multiple treatments. * evidence of any detectable tc-99m macroaggregated albumin flow to the stomach or duodenum, after application of established angiographic techniques to stop such flow. * previous radiation therapy to the lungs and/or to the upper abdomen * pregnancy * symptomatic lung disease. * significant extrahepatic disease representing an imminent life-threatening outcome. * active uncontrolled infection * any pre-treatment laboratory findings within 30 days of treatment demonstrating: * aspartate or alanine aminotransferase level greater than 5 times upper normal limit. * serum bilirubin greater than 2 mg/dl * infiltrative tumor on imaging * tumor volume greater than 70% of liver volume * tumor volume greater than 50% of liver volume and serum albumin level less than 3 mg/dl
effects of micronutrient (chromium) supplementation on diabetes

Conditions: Diabetes Mellitus, Type 1

Summary: 6-8% of usa population has diabetes. intensive blood glucose control dramatically reduces the devastating complications that result from poorly controlled diabetes. however, for many patients, achievement of tight glucose control is difficult with current regimens. trivalent chromium, the form found in foods and dietary supplements, is believed to be safe. our preliminary studies have reported that chromium supplementation inhibits the increase in pro-inflammatory cytokines (tumor necrosis factor-alpha and interleukin-6; tnf-alpha and il-6) secretion levels caused by high glucose levels in cultured monocytic cells. similarly, animal studies have shown that chromium niacinate supplementation lowered blood levels of glycemia and pro-inflammatory cytokines in streptozotocin-treated diabetic rats. cytokines are proteins that are secreted by monocytes and other cells in response to various stimuli, such as infection. some of the cytokines are known to regulate insulin sensitivity and elevated level of these cytokines in blood may accelerate clogging of arteries. thus, chromium supplementation may increase insulin sensitivity and glycemic control in diabetic patients, and may prevent the development of cardiovascular disease in diabetic patients. given the enormous public health cost of diabetes, the prospect of being able to use a relatively low-cost dietary supplement, such as chromium, as an adjuvant therapy to help in achieving normal blood glucose level merits further study. we will examine the effects of placebo and chromium niacinate supplementation on the fasting glucose, cholesterol, triglycerides, and markers of vascular disease in blood of diabetic patients. we will determine these above parameters at baseline and after the 1, 2 and 3 months of supplementation in diabetic patients. the long-term objective is to explore the efficacy of chromium as an adjuvant treatment for better glycemic control, prevent the development of cardiovascular disease (cvd), and improve the life expectancy in diabetic population. chromium supplements are widely used by the public and are available in many stores, such as wal-mart, walgreens, and many other food and drug stores. chromium is an essential trace metal and micronutrient present in wide variety of vegetables. niacin is a vitamin b6, an essential vitamin for our body. this study plans to use chromium niacinate, a complex of chromium and niacin. chromium niacinate is considered a nutrient.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of type 1 diabetes mellitus * participants between the ages of 8 and 21 exclusion criteria: * subjects with sickle cell disease, renal or liver disease * serum positive pregnancy test or breastfeeding * participants unwilling/unable to take supplements in pill form * participants taking prescription medication or supplements

Keywords: diabetes mellitus, juvenile onset cardiovascular diseases hyperglycemia hyperketonemia
small bioactive molecules in early copd diseases

Conditions: Chronic Obstructive Pulmonary Disease

Summary: to study the predictors contribute to the progression of copd by follow-up of patients with early copd and analyze their changes in bioactive molecular, exhaled gas, ct image, lung function, patient's symptoms and life quality.

a research found that nearly 40% of patients with chronic respiratory symptoms who showed significant airway inflammation (airway wall thickening and/or lung structure destruction (emphysema) on chest ct had advanced copd within 5 years, although their current lung function failed to meet diagnostic criteria for copd. current spirometry-based diagnostic methods are not the best predictors of copd progression and death. ct indicated emphysema and airway inflammation were recognized as better predictors of disease progression and mortality. based on a large cohort study, some scholars proposed the concept of "early copd", focusing on people under the age of 50, smoking for more than 10 pack years, having one of the manifestations of early airflow limitation, abnormal chest ct, and rapid decline of fev1, to study the mechanism of disease progression and early intervention methods.\[4\] in this study, we enroll participants with early copd symptoms, to detect the progression of copd with 3 years of follow-up. the predictors of disease progression and variants of bioactive molecular were analyzed, so as to clarify the progressive mechanism of copd.

Eligibility criteria:
inclusion criteria: * 1. \<60 years old; 2. smoking ≥ 10 pack years. 3. with any of the following anomalies: a. post-bronchodilator fev1/fvc\ 60 ml/yr). exclusion criteria: * 1. with other known chronic lung diseases, including bronchiectasis, interstitial pulmonary disease, tuberculosis, and pulmonary vascular disease (cteph). 2. with severe pleural disease and/or lesions of the sternum or ribs. 3. suffering from serious uncontrolled other systemic diseases, including chest and abdominal surgery, heart attack (angina pectoris, myocardial infarction, malignant arrhythmia, etc.) and cerebrovascular disease (stroke) within 3 months, as well as kidney disease (aki), cirrhosis, and any malignant tumor except lung cancer. 4. suffering from severe cognitive impairment. 5. with active tuberculosis or are taking anti-tuberculosis treatment. 6. pregnancy or lactation. 7. previous lung surgery. 8. acute upper and lower respiratory system infection within 4 weeks.
efficacy of dentifrices containing arginine versus fluoride on microbial acid

Conditions: Dental Caries

Summary: this study will be conducted to evaluate the effect of arginine versus fluoride containing toothpaste on neutralization of microbial acid produced by cariogenic bacteria in adult population using chair side assessment method.

.28 volunteer participants will be assigned in this study. participants will be randomly divided into two groups(n=14) according to type of toothpaste d where groups d1 patient will use arginine containing toothpaste while groups d2 the patient will used the fluoride toothpaste with a number of 14 patients in each group. the ph will be evaluated according to time in relation to the brushing with toothpaste (t) where (t0) represent salivary ph before brushing with toothpaste , (t1) represent salivary ph 10 minutes after brushing with toothpaste at fixed time of the day.

Eligibility criteria:
inclusion criteria: * participants should be over 18 years of age. * systematically healthy. * not taking any medication interfering with saliva secretion. * participants who signed informed consent. exclusion criteria: * participants with a compromised medical history. * participants under systemic disease treatment, with antibiotic, steroid or any medication known to cause dry mouth. * severe or active periodontal disease. * history of allergies or other adverse reactions to arginine, or oral care product or their ingredient.
observational study to evaluate the efficacy and safety of teneligliptin

Conditions: Type 2 Diabetes Mellitus

Summary: this study is designed as a prospective, observational, multi-centre study to evaluate the efficacy and safety of teneligliptin when switched from other dpp-4 inhibitors in type 2 dm with inadequate glycemic control


Eligibility criteria:
inclusion criteria: 1. the subject is aged ≥19 years 2. the subject has a documented diagnosis of type 2 diabetes mellitus for at least 3 months at the screening visit. 3. patient who was treated with same dosage of dpp4 inhibitor for at least 12 weeks prior to baseline visit (if patient who has been treated with dpp4 inhibitor and any other antidiabetic drugs, antidiabetic drugs should also have been kept same dosage for at least 12 weeks prior to baseline.) 4. patient with hba1c≥7.0% at baseline visit 5. patient who can be switched to teneligliptin instead of using dpp-4 inhibitor for glycemic control based on the investigator's judgment 6. patient (or legal guardian, if applicable) is informed of the full nature and purpose of the study, including possible risks and side effects, and understand this information, voluntarily signed and dated the written informed consent in compliance with protocol before inclusion in the study exclusion criteria: 1. patient with hypersensitivity to the teneligliptin 2. patient who treat the teneligliptin prior to baseline visit 3. a pregnant or lactating female patient